15 relations: Almorexant, Clinical trial, Eisai (company), Filorexant, Hypocretin (orexin) receptor 1, Hypocretin (orexin) receptor 2, Insomnia, International Nonproprietary Name, JNJ-42847922, MIN-202, Orexin, Orexin antagonist, Orexin receptor, SB-649,868, Suvorexant.
Almorexant (INN, codenamed ACT-078573) is an orexin antagonist, functioning as a competitive receptor antagonist of the OX1 and OX2 orexin receptors, which was being developed by the pharmaceutical companies Actelion and GSK for the treatment of insomnia.
New!!: Lemborexant and Almorexant ·
Clinical trials are experiments done in clinical research.
New!!: Lemborexant and Clinical trial ·
is a Japanese pharmaceutical company headquartered in Tokyo, Japan.
New!!: Lemborexant and Eisai (company) ·
Filorexant (INN, USAN) (code name MK-6096) is an orexin antagonist which is or was under development by Merck for the treatment of insomnia.
New!!: Lemborexant and Filorexant ·
Orexin receptor type 1 (Ox1R or OX1), also known as hypocretin receptor type 1, is a protein that in humans is encoded by the HCRTR1 gene.
Orexin receptor type 2 (Ox2R or OX2), also known as hypocretin receptor type 2, is a protein that in humans is encoded by the HCRTR2 gene.
Insomnia, or trouble sleeping, is a sleep disorder in which there is an inability to fall asleep or to stay asleep as long as desired.
New!!: Lemborexant and Insomnia ·
An International Nonproprietary Name (INN) is an official generic and nonproprietary name given to a pharmaceutical drug or active ingredient.
JNJ-42847922 is a selective antagonist of the orexin OX2 receptor which is under investigation by Janssen Research & Development for the treatment of major depressive disorder and insomnia.
New!!: Lemborexant and JNJ-42847922 ·
MIN-202 is a selective, small-molecule antagonist of the OX2 receptor which is under development by Minerva Neurosciences in association with Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia.
New!!: Lemborexant and MIN-202 ·
Orexin, also called hypocretin, is a neuropeptide that regulates arousal, wakefulness, and appetite.
New!!: Lemborexant and Orexin ·
An orexin antagonist is a drug that inhibits the effect of orexin by acting as a receptor antagonist of the orexin receptor.
New!!: Lemborexant and Orexin antagonist ·
The orexin receptor (also referred to as the hypocretin receptor) is a G-protein-coupled receptor that binds the neuropeptide orexin.
New!!: Lemborexant and Orexin receptor ·
SB-649,868 is a dual orexin receptor antagonist in development by GlaxoSmithKline.
New!!: Lemborexant and SB-649,868 ·
Suvorexant (INN, USAN) (trade name Belsomra) is a selective, dual orexin receptor antagonist marketed by Merck & Co. for the treatment of insomnia.
New!!: Lemborexant and Suvorexant ·